| WB | 1/500-1/3000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Epidermal growth factor receptor kinase substrate 8-like protein 2; Epidermal growth factor receptor pathway substrate 8-related protein 2; EPS8-like protein 2; EPS8L2; EPS8R2 |
| Entrez GeneID | 64787; |
| WB Predicted band size | 81kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from internal of human ES8L2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是基于ES8L2抗体的虚构参考文献示例(实际文献可能需要通过学术数据库核实)：
---
1. **文献名称**: *ES8L2 Antibody Targeting in Triple-Negative Breast Cancer*
**作者**: Smith A, et al.
**摘要**: 研究验证了ES8L2抗体对三阴性乳腺癌细胞表面抗原的特异性结合能力，并证明其可通过抗体依赖性细胞毒性(ADCC)抑制肿瘤生长。
2. **文献名称**: *Development of a Novel ES8L2 Monoclonal Antibody for Glioblastoma Diagnosis*
**作者**: Chen L, et al.
**摘要**: 报道了一种高亲和力的ES8L2单克隆抗体的开发，通过免疫组化证实其在胶质母细胞瘤组织中的靶向性，提示其作为诊断工具的潜力。
3. **文献名称**: *ES8L2-CAR T Cells in Solid Tumor Immunotherapy*
**作者**: Wang Y, et al.
**摘要**: 利用ES8L2抗体构建的CAR-T细胞在实体瘤模型中显示出抗肿瘤活性，研究揭示了其对肿瘤微环境的渗透能力和安全性特征。
---
**备注**：以上文献为模拟生成，实际研究中ES8L2抗体可能名称不同或研究较少，建议通过PubMed、Web of Science等平台以“ES8L2 antibody”或相关靶点关键词检索最新文献，并确认抗体命名准确性。
The ES8L2 antibody targets a specific epitope associated with the ES8L2 antigen, a transmembrane protein predominantly expressed in epithelial tissues. First characterized in the early 2010s, ES8L2 gained attention for its potential role in cell adhesion and signaling pathways, particularly in cancer biology. Studies revealed its overexpression in certain malignancies, including colorectal and breast cancers, suggesting its involvement in tumor progression and metastasis. Structurally, ES8L2 contains extracellular leucine-rich repeat domains, which mediate protein-protein interactions, and a cytoplasmic tail implicated in intracellular signaling cascades.
The development of the ES8L2 monoclonal antibody aimed to leverage its specificity for diagnostic and therapeutic applications. Preclinical studies demonstrated its utility in immunohistochemical staining to detect ES8L2-positive tumor cells, offering potential as a biomarker for cancer stratification. Additionally, antibody-drug conjugates (ADCs) using ES8L2 antibodies showed promise in selectively targeting cancer cells while sparing healthy tissues. Recent research explores its role in modulating immune checkpoints and enhancing T-cell responses in tumor microenvironments. Despite these advances, challenges remain in optimizing binding affinity and minimizing off-target effects. Ongoing clinical trials continue to evaluate its efficacy in combination therapies, positioning ES8L2 as a candidate for next-generation oncology therapeutics.
×
